Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Researchers have consistently found that gastroparesis is more prevalent among people who take GLP-1s than those who dont
Correction 22 March 2024 : Daiichi Sankyo has been added as one of the companies sponsoring the development of patritumab deruxtecan in Table 4.
Initially monoclonal antibodies (mAB) targeting IGF-1R such as dalotuzumab (MK-0646), ganitumab (AMG479), cixutumumab (IMC-A12), and figitumumab (CP-751871) were investigated
At 10 active days per cycle, the total annual injection commitment at maximum frequency is only 30 days, making it one of the lowest-burden protocols in terms of active treatment time
All mice had free access to food and water and were maintained under 12 h of light/dark cycling conditions
US$ 23.48
US$ 26.95
US$ 27.55
US$ 22.07
